Agenus to present data on AGEN1884 and AGEN2034 at ASCO meeting
Agenus announced that data on its proprietary AGEN1884 and AGEN2034 antibodies have shown consistent clinical activity with a number of partial responses, stable disease and currently, one complete responder. Updated data on these agents will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, being held June 1-5. "Our lead CTLA-4 and PD-1 are advancing rapidly in the clinic with more than 100 patients treated. AGEN1884 is the most advanced anti-CTLA-4 antibody in the clinic with the potential to be the second to market. We are pleased to report that after the first 100 patients have been treated, our antibodies are clinically active and are advancing in combination in second-line cervical cancer, an indication for which patients have no effective therapies, and presents a path to BLA filing," said CEO Garo Armen.